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Abstract We examined the effect of angiopoietin-1 (Ang1) on
apoptosis in human umbilical vein endothelial cells (HUVECs).
Ang1 (5^1000 ng/ml) dose-dependently inhibited apoptosis under
a serum-deprived state. A significant apoptotic inhibition
occurred with as low as 50 ng/ml. Two hundred ng/ml of Ang1
inhibited to approximately 50% of the control apoptotic rates for
96 h. Furthermore, an augmented antiapoptotic effect of Ang1 by
the addition of 20 ng/ml vascular endothelial growth factor was
observed. This Ang1-induced strong antiapoptotic effect in
endothelial cells is a novel and intriguing finding and could be
an additional description of Ang1-induced direct biological
function.
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1. Introduction
Vascular endothelium, a monolayer of cells lining the inti-
ma of the blood vessels is involved in a variety of functions,
including coagulation, vascular permeability, vascular tonus
and remodeling [1]. Endothelial cells, which are in direct con-
tact with plasma and cellular components of blood, are the
targets of many cytokines and growth factors [2,3].
Apoptosis, a strategic biologic process of eliminating un-
wanted cells is involved in the regulation of cell number under
physiological and certain pathological conditions [4]. Apopto-
sis is associated with distinctive morphological and biological
events, such as cellular shrinkage, nuclear condensation, and
fragmentation of chromatin caused by cleavage endonuclease
at the internucleosomal linker region, yielding mono- and
polynucleosomal DNA fragments. Prevention of apoptosis
in vascular endothelial cells by several growth factors and
cytokines, such as the ¢broblast growth factor [5], vascular
endothelial growth factor (VEGF) [6], endothelin-1 [7] and
adrenomedullin [8], have been studied. These molecules not
only stimulate cell proliferation rate but also suppress apop-
tosis, thereby maintaining the surviving cell number.
The recent discovery of angiopoietin-1 (Ang1) and angio-
poietin-2 (Ang2) has provided insights into the molecular and
cellular mechanisms of blood vessel formation and mainte-
nance [9,10]. Ang1 exerts its biological function through bind-
ing to the endothelial cell tyrosine kinase receptor, Tie2 [9,10].
In vivo analysis by targeted gene inactivation revealed that
Ang1 recruited and sustained periendothelial support cells
[11], while Ang2 disrupted blood vessel formation in the de-
veloping embryo by antagonizing the e¡ects of Ang1 on Tie2
[10]. Interestingly, transgenic overexpression of Ang1 [12] or
gene transfer of Ang1 [13] increases vascularization in vivo. In
vitro experiments demonstrated that Ang1 is weak for prolif-
eration but is an e¡ective molecule for sprouting [14] and
chemotactic response [15,16] in endothelial cells. Although
the above results suggest an important role of Ang1 in endo-
thelial cells, its role as an apoptosis modulator has not been
described carefully to date.
Here we examined the e¡ect of Ang1 on apoptosis in cul-
tured human umbilical vein endothelial cells (HUVECs). Our
data indicate that Ang1 is a strong apoptosis survival factor in
endothelial cells, and the addition of VEGF to Ang1 pro-
duced an augmenting e¡ect for surviving apoptotic death.
2. Materials and methods
2.1. Cell culture and reagents
HUVECs and porcine pulmonary arterial endothelial cells
(PPAECs) were prepared from human umbilical cords and porcine
pulmonary arteries by collagenase digestion. The endothelial origin
of the cultures was con¢rmed by the presence of factor VIII by im-
muno£uorescence detection. HUVECs and PPAECs were maintained
in M-199 medium supplemented with 20% (v/v) fetal bovine serum at
37‡C in a 5% CO2 atmosphere. The cells used in this study were from
between passage 2 and 4. The recombinant human VEGF was pur-
chased from RpD systems.
2.2. Production of Ang1 recombinant protein
The full cDNA of human Ang1 was ampli¢ed from human adult
heart cDNA, as a template, by PCR for 30 cycles at an annealing
temperature of 52‡C using sense and antisense primers [9]. The am-
pli¢ed DNA was cloned into the pCR-Blunt vector (Invitrogen) and
sequenced. This human Ang1 cDNA was re-subcloned into the CMV
promoter-driven mammalian cell expression vector, pcDNA3.1/Myc-
His (Invitrogen), that has a DNA fragment (63 bp) encoding c-myc
and a 6UHis tag at the 3P-terminus of coding region as an open
reading frame (CMV-Ang1-M-H). The CMV-Ang1-M-H gene con-
struct was transfected into COS-7 cells using Lipofectamine Plus (Gib-
co BRL) and incubated at 37.5‡C for 96 h in Dulbecco’s modi¢ed
Eagle’s media (DMEM) with 2% fetal bovine serum under 5% CO2-
95% atmosphere. To determine the presence of recombinant Ang1, the
culture supernatant and cell lysates of COS-7 cells transfected with the
CMV-Ang1-M-H were puri¢ed by Ni-NTA Spin Column (Qiagen)
and were separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) system, and the proteins were electro-
transferred to nitrocellulose membranes [15]. The nitrocellulose mem-
branes were blocked by incubation in a blocking bu¡er, incubated
with an anti-myc or anti-His antibody, washed, incubated with horse-
radish peroxidase conjugated secondary antibody, and signals were
visualized by the ECL detection method according to the manufac-
turer’s protocol (Amersham). Based on the above Western blotting
result (Fig. 1), 1 l of the culture supernatant of COS-7 cells, trans-
fected with the CMV-Ang1-M-H, were transferred to Ni-NTA Agar-
ose Column (Qiagen) to obtain a fair amount of recombinant Ang1.
The binding protein was eluted with the pH 8.0 bu¡er containing
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250 mM imidazole. The elutes were dialyzed extensively against phos-
phate bu¡ered saline (PBS) and were concentrated using Centricon 10
(Amicon) at 4‡C. The salts were removed using the desalting column.
Approximately 60 Wg of recombinant Ang1 was obtained. The purity
of this protein was determined by silver staining after SDS-PAGE.
The glycosylation status of the recombinant Ang1 was determined
with PGNase-F treatment according to the manufacturer’s protocol
(NEB).
2.3. Bioassay for recombinant Ang1 in endothelial cells
The biological activity of recombinant Ang1 protein was assayed by
sprouting activity in PPAECs according to the studies described pre-
viously [14,17]. Brie£y, PPAECs were grown to con£uence on micro-
carrier (MC) beads (Sigma) and placed in a 2.5 mg/ml ¢brinogen gel
(Sigma) containing control bu¡er or various concentrations of re-
combinant Ang1, and 200 U/ml Trasylol (Bayer). Fibrin gels were
incubated in M-199 containing control bu¡er or the same concentra-
tion of recombinant Ang1, 1.0% heat inactivated fetal calf serum and
200 U/ml Trasylol. After 2^3 days the extent of sprouting was deter-
mined using phase-contrast inverted microscope (Zeiss). To detect the
nuclei of sprouting endothelial cells from MC beads, the ¢brin gel
containing beads was washed with PBS, ¢xed for 30 min in 4.0%
paraformaldehyde, stained with Hoechst 33425 for 30 min and ob-
served using a £uorescence microscope (Zeiss).
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Fig. 2. Sprouting activity of recombinant Ang1 protein in PPAECs grown on microcarrier (MC) beads. The extent of sprouting is determined
using phase-contrast (for bright ¢eld: A and C) and £uorescence (for Hoechst 33425 staining: B and D) inverted microscope (Zeiss). A and B:
control; C and D: 200 ng/ml of recombinant human Ang1 protein for 3 days. Note that no sprouting is observed in control, but active sprout-
ings are observed in the presence of Ang1. Fluorescence photographs reveal that most nuclei of endothelial cells are located on beads in control
(B), whereas most nuclei of endothelial cells have migrated from beads in the presence of Ang1 (D). All magni¢cations are U150. The detailed
procedures for ¢xation and staining are described in Section 2.
Fig. 1. A: Detection of recombinant Ang1 protein from the culture
medium and cell lysates of COS-7 cells transfected with CMV pro-
moter driven mammalian cell expression vector containing the hu-
man Ang1 cDNA with the 3P-terminal extension encoding c-myc
and 6UHis tags. The culture medium and cell extracts of COS-7
cells were collected at 48 h and 96 h after transfection, and sepa-
rated by SDS-polyacrylamide gel (10%) electrophoresis. Recombi-
nant Ang1 protein was detected by Western blotting analysis with
anti-myc antibody. CM, culture medium; CE, cell extracts. B: Com-
parison of molecular weights of recombinant Ang1 protein with (+)
or without (3) PNGase-F treatment. Each lane contains 1.0 Wg of
puri¢ed human recombinant Ang1 protein, and Western blotted
with an antibody to c-myc. The detailed procedures for puri¢cation
and de-glycosylation are described in Section 2. Arrowheads indicate
recombinant Ang1. Rainbow molecular marker (Amersham) was
used as estimation of molecular mass.
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2.4. Quantitative determination of apoptosis
HUVECs were plated onto gelatinized 24-well plates (5U104 cells
per well) in M-199 medium supplemented with 20% (v/v) fetal bovine
serum and incubated for 24 h. The wells were extensively washed with
PBS, and the medium was changed to serum-free M-199 medium
containing various concentrations of recombinant Ang1, VEGF (20
ng/ml) or Ang1 (200 ng/ml) plus VEGF (20 ng/ml) as indicated in the
text. Control cultures received serum-free M-199 medium with the
same amount of PBS. All £oating cells were collected with two PBS
washes, and all adherent cells were also collected after trypsinization.
The numbers and size distributions of the £oating and adherent cells
were determined with a Coulter Model ZF Particle Counter. To detect
the apoptotic cells in the adherent cells, the parallel wells were washed
with 0.9% sodium chloride, ¢xed for 15 min with 0.5% glutaraldehyde,
and stained with Hoechst 33425 and Sytox green nucleic acid stain-
ings. Apoptotic cells were counted by three independent, blinded in-
vestigators, in four di¡erent random locations using £uorescence mi-
croscopes (Zeiss). The number of apoptotic cells in the adherent cells
was con¢rmed by CytoDeath kit according to the manufacturer’s
protocol (Boehringer Mannheim) in the part of this experiment.
Both the nuclear stainings and the CytoDeath kit gave similar results.
Therefore, in this study the total apoptotic events were presented as a
percentage of the apoptotic (determined by nuclear staining) and
£oating cells in a given cell population.
3. Results and discussion
3.1. Production of Ang1 recombinant protein
Ang1 has characteristic protein structures that contain a
coiled-coil domain in the NH2-terminal portion and a ¢bri-
nogen-like domain in the COOH-terminal portion [9]. Ang1 is
known to be a glycosylated secretory protein from the peri-
cytes and vascular smooth cells around endothelial cells [9]. A
major band of V75 kDa was detected mainly in the culture
supernatant, but not in the cell lysate of COS-7 cells after
transfection (Fig. 1). These data indicated that the recombi-
nant Ang1 was e⁄ciently secreted from transfected cells. One
liter of the culture supernatant of COS-7 cells 96 h after trans-
fection and the puri¢cation using Ni-NTA Agarose Column
provided us with approximately 60 Wg of recombinant human
Ang1. The silver gel staining of the puri¢ed recombinant
Ang1 after SDS-PAGE revealed a single band of V75 kDa
and a purity of approximately 94% (data not shown). The
observed molecular mass of the major band was larger than
the calculated molecular mass of recombinant Ang1 (V58
kDa) since Ang1 contained several potential glycosylation
sites as previously described [9]. Therefore, our recombinant
Ang1 was treated with PGNase-F and Western blotted with
an antibody to c-myc to examine the glycosylation status.
Deglycosylation reduced the apparent molecular weight of
recombinant Ang1 from V75 kDa to the size predicted
from the amino acid sequence, 58 kDa (Fig. 1). These results
indicate that our recombinant Ang1 from transfected COS-7
cells is an e⁄ciently secreted glycoprotein.
3.2. Bioassay for recombinant Ang1 in endothelial cells
Ang1 is weak for proliferation but is an e¡ective molecule
for sprouting [14] and chemotactic response [15] in endothelial
cells in vitro. Therefore, the biological activity of the recombi-
nant Ang1 protein was determined by sprouting activity in
FEBS 21846 2-4-99
Fig. 3. Detection of apoptotic cells by morphological analysis of Sytox Green nucleic acid-stained nuclei. HUVECs, deprived of serum and in-
cubated for 24 h without (A) and with VEGF (20 ng/ml) (B), Ang1 (200 ng/ml) (C) or VEGF (20 ng/ml) plus Ang1 (200 ng/ml) (D). Arrows
indicate the apoptotic cells. All magni¢cations are U260. The detailed procedures for ¢xation and staining are described in Section 2.
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PPAECs. 200 ng/ml of recombinant Ang1 produced an active
sprouting activity, while the control bu¡er did not produce
sprouting activity (Fig. 2). This endothelial sprouting activity
was induced in a dose-dependent manner within a range of
10^1000 ng/ml (Kim et al., unpublished observation). These
results were consistent with the previous study [14]. Thus, our
puri¢ed recombinant Ang1 was biologically active in endothe-
lial cells.
3.3. Ang1 is an apoptosis survival factor for endothelial cells
Cultured human endothelial cells have been demonstrated
to undergo apoptosis under serum deprivation and apoptotic
cells were detached from culture plates [18]. Therefore, we
used the serum deprivation method for inducing an apoptosis
in HUVECs. The percent age of apoptotic cells increased
from 1.5% before serum deprivation to 11.3%, 39.3%,
77.6%, 93.0% and 96.3% at 12 h, 24 h, 48 h, 72 h and 96 h
after serum deprivation (Figs. 3 and 4). Thus, the HUVECs
underwent an active apoptosis during the initial 48 h after
serum deprivation. 20 ng/ml of VEGF inhibited to approxi-
mately 55^60% of control the apoptotic rate in HUVECs for
48 h in the serum-deprived state (Figs. 3 and 4). These results
were similar to others reported [6,19]. Notably, 200 ng/ml of
Ang1 also inhibited to approximately 55^60% of control the
apoptotic rate in HUVECs for 48 h under serum-deprived
state (Figs. 3 and 4). Thus, VEGF and Ang1 produced similar
antiapoptotic results in endothelial cells although the inhibi-
tory doses of 50% were 10 times di¡erent. In addition, we
determined the proliferation assay with Ang1 (200 ng/ml) us-
ing [3H]thymidine incorporated into HUVECs in the absence
and presence of 10% serum. Under both conditions, Ang1 did
not change the proliferative activity in HUVECs (data not
shown) as in other reports [9,14]. Therefore, the Ang1-induced
antiapoptotic e¡ect resulted from the cell survival but did not
result from the cell proliferation.
Furthermore, Ang1 (5^1000 ng/ml) dose-dependently inhib-
ited the apoptosis in HUVECs at 24 h in the serum-deprived
state (Fig. 4). A signi¢cant apoptotic inhibition was induced
with as low as 50 ng/ml and a maximal antiapoptotic e¡ect
(64.4 þ 10.7% survival of control apoptotic cells) was induced
with 1000 ng/ml of Ang1. These data suggest that the Ang1-
induced antiapoptotic e¡ect in endothelial cells may be medi-
ated by its speci¢c receptor, Tie2, binding. On the other hand,
Ang2 is a naturally occurring antagonist of Ang1 that com-
petes for binding to Tie2 and blocks Ang1-induced Tie2 au-
tophosphorylation [10]. Therefore, it is worth examining
whether Ang2 blocks the Ang1 induced antiapoptotic e¡ect
in endothelial cells through a Tie2 receptor. Furthermore, the
intracellular mechanism of Ang1 responsible for the antiapop-
totic e¡ect remains to be elucidated.
The augmented antiapoptotic e¡ect of Ang1 by addition of
VEGF was observed during serum deprivation in HUVECs
(Fig. 4). The addition of 20 ng/ml VEGF to 200 ng/ml Ang1
inhibited to approximately 75% of the control apoptotic rate
for 96 h. Similar to our results, the modulatory role of VEGF
on Ang1 has been observed in a mouse corneal micropocket
assay [20]. Ang1 failed to stimulate an angiogenic response
when administered alone. However, when co-administered
with VEGF, Ang1 augmented the formation of neovessels.
While Ang1 and VEGF are mainly synthesized from peri-
endothelial cells including vascular smooth muscle [9^11,20],
their receptors are mainly located in the endothelial cells dur-
ing embryonic development and the adult period [20,21].
Although the regulators for VEGF expression are well char-
acterized the regulators for Ang1 remain to be further eluci-
dated. Ang1 seems not to be upregulated by hypoxia [22].
However, enhanced expression of Ang1 and Tie2 has been
observed in glioblastoma, suggesting that Ang1 could be in-
volved in tumor angiogenesis [23]. Importantly, Ang1 and
Tie2 are expressed in normal adult vessels in which vasculo-
genesis or angiogenesis does not occur [10,11,21]. These con-
stitutive expressions of Ang1 and Tie2 may be involved in
apoptosis survival for the maintenance of endothelial cell in-
tegrity.
In summary, we examined the e¡ect of Ang1 on apoptosis
in cultured HUVECs. Our data indicate that Ang1 is a strong
apoptosis survival factor in endothelial cells. This Ang1-in-
duced antiapoptotic e¡ect in endothelial cells is a novel and
intriguing ¢nding and could be an additional description of
the Ang1-induced direct biological function.
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